News

Vertex Pharmaceuticals has agreed to acquire US-based biotech company Semma Therapeutics for $950m (£784.66m) in an all-cash deal with an aim to develop curative cell-based treatments for type

Results suggest that Entresto, an essential treatment for HFrEF, not only positively impacts a biomarker shown to be associated with prognosis of clinical outcomes in HFrEF, but also

Topline data from the study were published on 3 July 20191, which showed a significant reduction in hyperglycemia, body weight and waist size compared to placebo. The entire

The phase III trial has demonstrated that Xofluza was a well-tolerated and efficient potential treatment for flu in otherwise healthy children aged one to less than 12 years

The late-stage trials – ASCLEPIOS I and II probed the efficacy and safety of ofatumumab 20mg given as a once-monthly subcutaneous injection, in comparison to daily once oral

Anifrolumab has demonstrated a statistically-significant and clinically-meaningful reduction in disease activity compared to placebo in the trial.  Both arms received standard of care in the study. Anifrolumab is

VNRX-5133 is an injectable beta-lactamase inhibitor (BLI) that features selective and potent in vitro activity against both serine- and metallo-beta-lactamases (MBLs), including ESBL, OXA, KPC, NDM, and VIM

The Breakthrough Therapy Designation was based on Phase 1 and Phase 2 data evaluating nirogacestat as a monotherapy in patients with desmoid tumors. Desmoid tumors are rare and

The approval has been granted for Tecentriq plus chemotherapy (Abraxane [paclitaxel protein-bound particles for injectable suspension (albumin-bound); nab-paclitaxel]) to treat adult patients with unresectable locally advanced or metastatic